TB-500 is the widely-studied active fragment of thymosin β4, an actin-sequestering peptide central to cytoskeletal and tissue-research literature.
TB-500 corresponds to the bioactive fragment of thymosin β4 (Tβ4), a 43-residue actin-sequestering peptide. Published in-vitro literature describes G-actin binding, cytoskeletal reorganisation and angiogenesis-relevant signalling.
Research characteristics
- Actin binding via the LKKTETQ motif.
- Upregulation of VEGF and PGE2 pathways in cultured cell studies.
- Widely referenced in tissue-model repair literature.
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
